PTO/SB/08 (2/92) OCT 3 0 2006 Sheet 1 of 8 3 Attorney's Docket No. Application Serial No. Form PTO-1449 3910- ant(s) 09/904.786 39780-1618P2C47 INFORMATION DISCLOSURE STATEMENT ASHKENAZI, et al. **Group Art Unit:** Filing Date: 1646 (use several sheets if necessary) July 12, 2001 **U.S. PATENT DOCUMENTS** Subclass **Filing Date** Class Ref. Date Document No. Name Examiner (if appropriate) Initials No. 10/4/88 8/21/90 4.950,647 Robins et al. 1. 1/19/95 2. 7/15/97 5,648,376 Strobel et al. 5.801,193 Ojo-Amaize et al. 4/15/97 3. 9/1/98 6/7/95 10/6/98 5.817.306 Haskill et al. 4. 09/28/99 5.958.403 Storm, et al. 5. **FOREIGN PATENT DOCUMENTS Translation** Class Subclass Ref. Date Document No. Name Examiner YES Initials No. **OTHER DOCUMENTS** (including author, title, date, pertinent pages, etc.) Examiner Ref. Title Initials No. Abolhassani, M., "Antibacterial effect of borage (Echium amoenum) on Staphylococcus aureus," Brazilian Journal of N 6. Infectious Diseases 8:382-385 (2004). Amirghofran, Z. et al., "Echium amoenum stimulate of lymphocyte proliferation and inhibit fo humoral antibody 7. synthesis," Im. J. Med. Sci. 25:119-124 (2000). Chapoval, A. I. et al., "Combination chemotherapy and IL-15 administration induces permanent tumor regression in a 8. mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells," J. Immunol. 161:6977-6984 (1998). Fung-Leung, et al., "Tepoxalin, A Novel Immunomodulatory Compound, Synergizes with CSA in Suppression of Graft-9. Versus-Host Reaction and Allogeneic Skin Graft Rejection", Transplantation, 60:362-368 (1995). Gennari, R. et al., "Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived 10. sepsis by improving gut barrier function and modulating bacterial clearance," Annals of Surgery 220:68-76 (1994). Grabstein, K.H. et al., "Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor." 11. Science 264:965-968 (1994) Kasajan, M.T. et al., "IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity," Immunity 16:559-569 (2002).

EXAMINER:		DATE CONSIDERED: ,		
	VINA	10/10		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
conformance and not considered. Include a copy of this form with next communication to applicant.				

following subcutaneous application," Br. J. Clin. Pharmacol. 46:5-10 (1998).

perforin but are independent of INF-y," J. Immunol. 171:608-615 (2003).

Immunol. 142:1834-1839 (1989).

J. Immunol. 153:1697-1706 (1994).

Sci. USA 86:5069-5073 (1989).

5094 (2005).

Kirchner, G.I. et al., "Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients

Ma, H-L et al., "IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require

Nastala, C.L. et al., "Recombinant IL-12 administration induces tumor regression in association with IFN-y production,"

Pahwa, R. et al. "Recombinant interleukin 2 therapy in severe combined immunodeficiency disease," Proc. Natl. Acad.

Patterson, S. et al., "Human invariant NKT cells are required for effective in vitro alloresponses," J. Immunol. 175:5087-

Naito, K. et al., "Macrophage factors which enhance the mixed leukocyte reaction initiated by dendritic cells," J.

'if an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filling date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2241833 v1

13.

14.

15.

16.

17.

18.

			OCT 3	3 0 2006	PTO/SB/08 (2/92) Sheet 2 of &
		Form PTO-1449	HAR	Attomey's Docket No. 39789-1618P2C47	Application Serial No. 09/904,786
INFO	RMATIO	N DISCLOSURE STAT	EMENT	pplicant(s)	
					ASHKENAZI, et al.
(use several sheets if necessary)			ry)	Filing Date: July 12, 2001	Group Art Unit:
ph	19.	deficiency syndrome,"	Infect. Immun	iol. <u>44</u> :339-343 (1984).	Il activity in homosexual men with acquired immune
-	20.	Santoli, D. et al., "Auto lymphocyte reaction: a (1986).	logous B lymp inalysis of the	phoblastoid cell lines and lon role of HLA class II antigens	ng-term cultured T cells as stimulators in the mixed as stimulatory molecules," <i>J. Immunol.</i> 137:400-407
	21.	Shim, et al., "Immunos Proc. Natl. Acad. Sci.,			and in vitro via T cell-specific Apoptosis Induction,"
	22.	Tarr, P.E. et al., "Granu (1996).	ilocyte-macroj	phage colony-stimulating fac	tor and the immune system," <i>Med Oncol.</i> <u>13</u> :133-140
	23.	galactosylceramide,"	l. Immunol. <u>16</u>	<u>3</u> :2387-2391 (1999).	etastasis by dendritic cells pulsed with α-
V	24.	Tsavaris, N. et al., "Imr Br. J. Cancer 87:21-27		in patients with advanced b	reast cancer undergoing chemotherapy with taxanes,"
			· <del>·</del>		
	<del></del>				
<u> </u>					· ·
•					
		•			· · · · · · · · · · · · · · · · · · ·
		·		·	
			·		
		i			

EXAMINER:	J.m.	° W	DATE CONSIDERED:
			conforms with MPEP 609. Draw a line through the citation if not in ext communication to applicant.
			rovided because the reference was previously cited by or submitted to the upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).
SV 2241833 v1			

طن ط!	OCT 3 0 2006	PTO/SB/08 (2/5 Sheet 3 o
Form PTO-1449	Attorney's Docket No.	Application Serial No. 09/904,786
INFORMATION DISCLOSURE STAT	EMENT Applicant(s)	ASHKENAZI, et al.
	Filing Date:	Group Art Unit:
(use several sheets if necessa	July 12, 2001	1646
<del>                                     </del>		

Ì	EXAMINER:	Λ.		DATE CONSIDERED:	
		1/1/~~	( h	1/1/27_	
	EXAMINER: Initial in citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in				
	conformance and not considered. Include a copy of this form with next communication to applicant.				
	"If an actorick	le placed beside t	ha reference number a convile not provi	ded because the reference was previously sited by or submitted to the	_

provided because the reference pumber, a copy is not provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provided because the reference was previously cited by or submitted to to provide the provided because the reference was previously cited by or submitted to to provide the provided because the reference was previously cited by or submitted to the provided because the reference was previously cited by or submitted to the provided by the